English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND While central carbon metabolism has been studied extensively in cancer, lipidomic research is sparse. Sphingolipids participate in cellular functions including secondary messengers, lymphocyte trafficking, inflammation, angiogenesis, migration, proliferation, necrosis and apoptosis, thus highlighting the importance of understanding their role to tumor phenotype. Our investigation into metabolic alterations involving sphingolipid pathway in patient-derived IDH1mut glioma cultures aimed to identify points of metabolic vulnerability. METHODS Dysregulation of sphingolipid metabolism was interrogated for brain tumor cultures via LCMS. Expression of enzymes within the pathway was assessed for IDHmut 1/2 and IDHWT glioblastoma patient cohorts via The Cancer Genome Atlas (TCGA) analysis and Western blot for tumor cultures. Biostatic drug response was examined via viability and cytotoxicity assays. RESULTS We probed the effect that decreasing D-2HG levels with IDH1mut inhibitor (AGI5198) treatments had on sphingolipid metabolism in tumor cultures. The probe revealed N,N-dimethylsphingosine (NDMS), and sphingosine were significantly elevated, while sphingosine-1-phosphate (S1P) was downregulated in IDH1mut cultures following treatment. Drug panel screening revealed that SPHK inhibitor (SPHKi), N,N-dimethylsphingosine in combination with sphingosine triggered lethal dose-dependent response in IDH1mut cultures; contrary to IDHWT. Westerns presented differential expression of SPHK1 and SPHK2 in IDHWT glioblastoma cells, while IDHmut exclusively expressed SPHK1. CONCLUSION This novel discovery showed how targeting sphingolipid metabolism in IDH1mut gliomas presents therapeutic implications. Elevated S1P was reported particularly for malignant glioblastomas in prior studies; whereas our research revealed relatively low S1P in the IDHmut compared with IDHWT cultures. In addition to reduced or silenced expression of SPHK2, we postulate that S1P levels in IDHmut gliomas might be closer to a critical threshold allowing treatment with SPHK1i to effectively suspend proliferation and anti-apoptotic defense mechanisms. Our findings revealed that the manipulation of pivotal, endogenous sphingolipids can ultimately trigger apoptosis in IDHmut gliomas. Future studies will probe these targets in preclinical models.

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1MUT GLIOMA